Anika Therapeutics | ANIK - Operating Profit


Anika Therapeutics reported $646K in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Abbott USD 2.25B 73M Dec/2025
Agenus USD 14.4M 19.26M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Integra LifeSciences USD 66M 54.24M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
J&J USD 5.59B 1.81B Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Merit Medical Systems USD 54.2M 11.58M Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 1.7B 2.17B Dec/2025
Smith & Nephew USD 440M 50M Dec/2025
Stryker USD 1.97B 609M Dec/2025
Surmodics USD -5.64M 276K Sep/2024
Veracyte USD 24.63M 1.52M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025
Zimmer Biomet Holdings USD 302.9M 35.4M Dec/2025